Pantoprazole-d8

Pantoprazole-d8 (BY1023-d8) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) [1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) [3][4].

Product Specifications

CAS Number

[934294-34-5]

Product Name Alternative

BY1023-d8; SKF96022-d8

UNSPSC

12352005

Target

Apoptosis; Autophagy; Bacterial; Isotope-Labeled Compounds; Proton Pump

Related Pathways

Anti-infection; Apoptosis; Autophagy; Membrane Transporter/Ion Channel; Others

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Smiles

[2H]C([2H])([2H])OC(C(OC([2H])([2H])[2H])=C([2H])C([2H])=N1)=C1CS(C2=NC3=CC(OC(F)F)=CC=C3N2)=O

Molecular Formula

C16H7D8F2N3O4S

Molecular Weight

391.42

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013 Dec 15;19 (24) :6766-76.|[3]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :1322-1330.|[4]W Beil, et al. Pantoprazole: a novel H+/K (+) -ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218 (2-3) :265-71.|[5]K Takeuchi, et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14 (3) :251-7.